Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Long-Term Investments (2017 - 2025)

Historic Long-Term Investments for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $11.8 million.

  • Innate Pharma's Long-Term Investments rose 552.02% to $11.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $11.8 million, marking a year-over-year increase of 552.02%. This contributed to the annual value of $11.1 million for FY2024, which is 501.12% up from last year.
  • Latest data reveals that Innate Pharma reported Long-Term Investments of $11.8 million as of Q2 2025, which was up 552.02% from $11.0 million recorded in Q4 2024.
  • Innate Pharma's 5-year Long-Term Investments high stood at $48.3 million for Q2 2021, and its period low was $10.5 million during Q4 2023.
  • Over the past 5 years, Innate Pharma's median Long-Term Investments value was $35.8 million (recorded in 2022), while the average stood at $27.8 million.
  • As far as peak fluctuations go, Innate Pharma's Long-Term Investments plummeted by 9986.91% in 2021, and later surged by 552.02% in 2025.
  • Innate Pharma's Long-Term Investments (Quarter) stood at $45.6 million in 2021, then dropped by 21.46% to $35.8 million in 2022, then crashed by 70.58% to $10.5 million in 2023, then increased by 4.23% to $11.0 million in 2024, then increased by 7.05% to $11.8 million in 2025.
  • Its Long-Term Investments stands at $11.8 million for Q2 2025, versus $11.0 million for Q4 2024 and $11.1 million for Q2 2024.